Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
NVR
NVR
$16.7B
| $75.7M | 0.07% |
23,218
-794
| -3% | -$2.43M |
|
327
Fomento Económico Mexicano
FMX
$40.1B
| $75.4M | 0.07% |
1,216,250
+485,750
| +66% | +$30.9M |
|
328
American Tower
AMT
$79.9B
| $74.9M | 0.06% |
289,639
-1,108,570
| -79% | -$274M |
|
329
Essex Property Trust
ESS
$18.1B
| $74.8M | 0.06% |
326,229
-234,400
| -42% | -$56.2M |
|
330
RTX Corp
RTX
$298B
| $74.7M | 0.06% |
+1,211,746
| New | +$75.6M |
|
331
Deckers Outdoor
DECK
$12.7B
| $74.2M | 0.06% |
2,267,388
+815,388
| +56% | +$22.5M |
|
332
Mastercard
MA
$488B
| $74M | 0.06% |
250,400
-6,100
| -2% | -$1.72M |
|
333
Mondelez International
MDLZ
$78.6B
| $74M | 0.06% |
1,447,298
+698,085
| +93% | +$35.9M |
|
334
Grupo Aeroportuario del Pacifico
PAC
$12.7B
| $74M | 0.06% |
1,029,800
-95,700
| -9% | -$6.1M |
|
335
Petrobras Class A
PBR.A
$104B
| $73.6M | 0.06% |
9,235,119
-2,341,700
| -20% | -$16.4M |
|
336
Sarepta Therapeutics
SRPT
$1.93B
| $73.2M | 0.06% |
456,478
+376,800
| +473% | +$51.3M |
|
337
SPS Commerce
SPSC
$2.65B
| $72.7M | 0.06% |
968,263
-27,000
| -3% | -$1.65M |
|
|
EQC
338
DELISTED
Equity Commonwealth
EQC
| $72.4M | 0.06% |
2,247,385
+1,340,548
| +148% | +$44.3M |
|
339
Ambarella
AMBA
$3.65B
| $72.2M | 0.06% |
1,576,633
+79,900
| +5% | +$4.12M |
|
340
NIO
NIO
$11.5B
| $71.8M | 0.06% |
+9,300,100
| New | +$40.9M |
|
341
Qorvo
QRVO
$8.51B
| $71.2M | 0.06% |
644,506
-1,312,948
| -67% | -$130M |
|
|
CTXS
342
DELISTED
Citrix Systems Inc
CTXS
| $71.2M | 0.06% |
481,479
-90,300
| -16% | -$13M |
|
|
COR
343
DELISTED
Coresite Realty Corporation
COR
| $71M | 0.06% |
586,800
-333,900
| -36% | -$40.1M |
|
344
Pultegroup
PHM
$24.6B
| $71M | 0.06% |
2,087,367
-316,210
| -13% | -$9.49M |
|
345
Eldorado Gold
EGO
$10.5B
| $70.7M | 0.06% |
7,291,433
-826,540
| -10% | -$7.18M |
|
|
SJR
346
DELISTED
Shaw Communications Inc.
SJR
| $70.3M | 0.06% |
4,296,800
-81,700
| -2% | -$1.35M |
|
|
VIVO
347
DELISTED
Meridian Bioscience Inc
VIVO
| $70.2M | 0.06% |
3,013,964
-138,200
| -4% | -$2M |
|
348
CVS Health
CVS
$120B
| $70.1M | 0.06% |
1,079,184
-192,069
| -15% | -$12.1M |
|
349
Thermo Fisher Scientific
TMO
$221B
| $69.5M | 0.06% |
191,917
+65,500
| +52% | +$22M |
|
|
MODV
350
DELISTED
ModivCare
MODV
| $68.8M | 0.06% |
872,499
-39,800
| -4% | -$2.69M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.